News | August 31, 2021
Sun Pharma to commercialise Winlevi in the US and Canada
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
Sun Pharma has committed Rs. 100 crores towards these initiatives
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
Subscribe To Our Newsletter & Stay Updated
